PepGen Inc

NASDAQ: PEPG
$13.96
+$0.01 (+0.1%)
Closing price May 7, 2024

PEPG Chart and Intraday Price

PEPG Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 1 MARINA PARK DRIVE, SUITE 900, BOSTON, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 520.93M USD
Shares Outstanding 31,343,500
PepGen Inc. is a pioneering biotechnology firm based in Boston, Massachusetts, dedicated to advancing the treatment of severe neuromuscular and neurologic diseases. With a focus on oligonucleotide therapeutics, its flagship product, PGN-EDO51, is currently undergoing Phase I clinical trials aimed at combating Duchenne muscular dystrophy. Additionally, PepGen is exploring treatments for myotonic dystrophy type 1 and other forms of muscular dystrophy, demonstrating its commitment to addressing unmet medical needs in the neuromuscular field since its inception in 2018.

PEPG Articles

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
A beneficial owner stepped up and took a controlling stake in a struggling retailer, while public offerings of stock prompted insider buying at some biotech companies.
Trey Thoelcke
Published: